Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) has released the proxy form for its 2025 Annual General Meeting, to be held on 26 June 2026 at 2:30 p.m. on the 15th Floor, Building 7, No. 6, Lane 100, Pingjiaqiao Road, Pudong New Area, Shanghai.

Shareholders will vote on 11 ordinary resolutions: 1) the 2025 Board report; 2) the 2025 annual report and summary; 3) the 2025 profit distribution plan; 4) approval of 2026 financing and credit lines from financial institutions; 5) director remuneration for 2026; 6) appointment of both PRC and overseas auditors for 2026; 7) formulation of remuneration policies for directors and senior management; 8) a three-year (2026–2028) dividend distribution plan; 9) election of an independent non-executive director for the fourth board session; 10) equity changes in entities executing certain investment sub-projects; 11) an external investment and connected transaction.

Three special resolutions are also proposed: 12) an estimated external guarantee quota for 2026; 13) a general mandate to issue domestic and/or overseas debt-financing instruments; 14) a general mandate to issue additional A Shares and/or H Shares.

The proxy form must be lodged with the H-share registrar, Tricor Investor Services Limited, no later than 24 hours before the meeting. Completion of the proxy does not preclude shareholders from attending and voting in person.